Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 39 Pharmacology (model) PhD Projects, Programmes & Scholarships

Discipline

Discipline

Medicine

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


Pharmacology (model) PhD Projects, Programmes & Scholarships

We have 39 Pharmacology (model) PhD Projects, Programmes & Scholarships

Personalising cancer treatment with tumour evolution modelling using AI-based genomics biomarkers and PK/PD

Tumour heterogeneity is a major problem limiting the efficacy of targeted oncological therapies. Most advanced tumours eventually become resistant to the treatments, ultimately making the patient succumb to metastatic disease. Read more

Vascularisation of tumour organoids for mechanistic and drug development

Gliomas such as are the most common form of brain tumour, a subset Glioblastoma (GBM) are devastating adult brain cancer with high rates of recurrence and treatment resistance. Read more

Cardiac Harmony: Modelling Heart Beats with Stem Cells and Code

Despite significant advancements in cardiac research, heart disease remains a leading cause of mortality globally. Unexpected cardiac events can occur even in young, fit individuals engaged in routine activities. Read more

Neurovascular coupling in cerebral hypoperfusion

There are almost a million people living with dementia in the UK. Most of these cases comprise Alzheimer’s Disease (AD), vascular dementia (VaD) or, as is increasingly recognised, a mixed picture phenotype with evidence of the two conditions co-existent in the same patient. Read more

New Drugs for Brain Tumours: Prodrugs of Diazopropyne

  Research Group: Medicines Development and Pharmaceutical Sciences
The propargyl group, introduced to temozolomide-like drugs for brain tumours by our colleagues in Nottingham, shows considerable pre-clinical promise and… Read more

Development of Naked Mole Rat Colonic Crypt Models to Use in the Search for Bowel Disease Preventatives

  Research Group: Institute of Cancer Therapeutics
Diseases affecting the bowel such as colorectal cancer (CRC) and the inflammatory bowel diseases (IBD) ulcerative colitis and Crohn’s disease are major global healthcare challenges in the 21st century. Read more

Network-based predictive modelling of cardiovascular disease risk

The risk of cardiovascular disease (CVD) is orchestrated by multiple factors. QRISK models (currently QRISK3) have been used in the UK to estimate CVD risk within the next 10 years for individuals without CVD. Read more

Investigating the links between β-amyloid, osteoporosis and frailty in Alzheimer’s disease

Background. Individuals with Alzheimer’s disease are more likely to suffer from osteoporosis (the loss of bone mass and strength) than age-matched individuals1, significantly contributing to the frailty associated with dementia. Read more

Integrated omics approach to psychiatric disorders

  Research Group: Chemistry and Biosciences
In psychiatry, the selection of antipsychotics and antidepressants is led by a trial-and-error approach. The prescribing of these medications is complicated by sub-optimal efficacy and high rates of adverse drug reactions (ADRs). Read more

Identifying cognitive and biochemical changes underlying lifestyle risk factors for dementia

  Research Group: Pharmacology and Experimental Therapeutics
Dementia describes a group of age-associated conditions of which cognitive decline is a major feature. Alzheimer’s disease (AD) is the most common cause of dementia and is characterised by the onset of a gradual cognitive decline. Read more

Endosomal Sorting Complex Required for Transport (ESCRT): Investigation of the role in acquired drug resistance in colon cancer

  Research Group: Institute of Cancer Therapeutics
Despite treatment advances, one of the most common cancers, colorectal cancer (CRC), still has a 45% mortality rate, and one of the major problems is the build-up of resistance to cancer drugs during treatment (‘acquired resistance’) such that over time the drugs stop working. Read more

Filtering Results